Heterologous Prime-Boost Vaccination in Tumor Immunotherapy
Most of the vaccine strategies under development use multiple immunizations with the same agent such as a viral vector encoding a tumor antigen. More recently, the concept of heterologous prime-boost immunization has been tested in animal models. This strategy involves the sequential administration of different delivery vectors encoding the same recombinant antigen (1). Initially demonstrated in animal studies of infectious diseases, such as malaria (1,2) and AIDS (3), prime-boost technology is now being developed for use in tumor patients (4).
KeywordsDelivery Vector Recombinant Antigen Semliki Forest Virus Recombinant Vaccinia Virus Immunotherapy Strategy
Unable to display preview. Download preview PDF.
- 5.Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964–3973.PubMedGoogle Scholar
- 6.Oertli D, Marti WR, Zajac P, et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 2002; 13:569–575.PubMedCrossRefGoogle Scholar
- 19.Tuettenberg A, Jonuleit H, Tuting T, Bruck J, Knop J, Enk AH. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumorspecific CD8(+) T cells: implications for an efficient vaccination strategy. Gene Ther 2003; 10:243–250.PubMedCrossRefGoogle Scholar